CBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Crescent Biopharma Inc (CBIO) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has potential in the oncology space with promising pipeline developments and positive analyst ratings, the lack of significant financial growth, absence of recent news catalysts, and neutral trading trends suggest a wait-and-see approach. Additionally, there are no strong proprietary trading signals to support immediate action.
The MACD is positive but contracting, RSI is neutral at 48.639, and moving averages are converging, indicating no strong directional trend. The stock is trading near its pivot level of 11.969, with support at 10.863 and resistance at 13.074.
and a promising oncology pipeline, including CR-001 and ADC developments. Analysts project significant revenue potential by 2036.
No recent news or significant trading trends. Financial performance shows no revenue growth, negative EPS (-1.49), and a net loss of -$24.6M. Congress trading data is unavailable.
In Q3 2025, revenue remained at $0 with no growth. Net income improved by 150.47% YoY but is still negative at -$24.6M. EPS dropped significantly by -90.22% YoY to -1.49.
Analysts are bullish with price targets ranging from $22 to $35 and Buy/Overweight ratings. They highlight the potential of CR-001 and the ADC pipeline but note that significant data is 12-15 months away.
